Its lack of vaccine-development success stories makes its prospects for a COVID-19 vaccine dubious, but there are positive signs for investors.
News & Analysis: Novavax
The clinical biotech is benefiting from an analyst upgrade and optimism about its pipeline.
Instead of buying one COVID-19 vaccine lottery ticket, buy them all. Good idea or not?
The biotechnology companies creating COVID-19 vaccines should give hope to patients and investors. Moderna and Novavax are no exception.
With Novavax racing to develop a vaccine for the coronavirus, is now a good time to buy shares of the biotech company?
Gravity could kick in for this high-flying biotech stock. But, then again, it might not.
Another $384 million in funding for its COVID-19 vaccine program gave the biotech a big shot in the arm.
The big investment from CEPI will enable the biotech to fund clinical development of its COVID-19 vaccine candidate and rapidly scale up production.
NVAX earnings call for the period ending March 31, 2020.
The most likely reason? Anticipation.